Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Anti-CD20 antibody wows in multiple sclerosis

Nature Biotechnology volume 33, pages 1215–1216 (2015)Cite this article

Subjects

The recent data for ocrelizumab conclusively confirm what was first recognized almost a decade ago. Mature B cells, which express CD20, play a central role in the pathophysiology of an autoimmune condition traditionally considered to be driven by aberrant T helper (TH) cell responses.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Dublin

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Anti-CD20 antibody wows in multiple sclerosis. Nat Biotechnol 33, 1215–1216 (2015). https://doi.org/10.1038/nbt1215-1215

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1215-1215

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research